References: Mawardi HH, Almazrooa SA, Dakhil SA, Aboalola AA, Al-Ghalib TA, Eshky RT, Niyazi AA, Mawardi MH
A blinded extension among participants with baseline BMI 35 reached 30.3% mean weight loss at 104 weeks
The post Eli Lilly Files Suit Challenging the FDAs Drug Classification of Retatrutide appeared first on Big Molecule Watch.
Here's what those terms actually mean: FDA facility registration is a legal requirement for supplement manufacturers - it means the facility is on record with the FDA, not that the FDA has evaluated or approved the specific product made there
The impact on lifestyle and health was significant, with 97% noticing at least one aspect of their health had improved with weight loss, with increased mobility and improved energy levels often being cited
Retatrutide is classified as a next-generation multi-receptor research peptide and is supplied strictly for research use only